Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.500
-0.060 (-2.34%)
At close: Jun 6, 2025, 4:00 PM
2.520
+0.020 (0.80%)
After-hours: Jun 6, 2025, 7:18 PM EDT
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $5.87M in the quarter ending March 31, 2025, a decrease of -36.61%. This brings the company's revenue in the last twelve months to $44.58M, down -59.83% year-over-year. In the year 2024, Spero Therapeutics had annual revenue of $47.98M, down -53.77%.
Revenue (ttm)
$44.58M
Revenue Growth
-59.83%
P/S Ratio
3.13
Revenue / Employee
$1,393,250
Employees
32
Market Cap
139.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SPRO News
- 9 days ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 9 days ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire
- 24 days ago - Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewsWire
- 2 months ago - Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 - GlobeNewsWire